• 1
    Abbott D, Comby P, Charuel C, Graepel P, Hanton G, Leblanc B, Lodola A, et al. Preclinical safety profile of sildenafil. Int J Impot Res 2004; 16: 498504.
  • 2
    Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003; 57: 597600.
  • 3
    Anderson PC, Gommersall L, Hayne D, Arya M, Patel HR. New phosphodiesterase inhibitors in the treatment of erectile dysfunction. Expert Opin Pharmacother 2004; 5: 22419.
  • 4
    Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 34651.
  • 5
    Fournier G Jr, Juenemann KP, Lue TF, Tanagho EA. Mechanism of venous occlusion during canine penile erection: an anatomic demonstration. J Urol 1987; 137: 1637.
  • 6
    Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high-density lipoprotein cholesterol as important predictors of erectile dysfunction [see comments]. Am J Epidemiol 1994; 140: 9307.
  • 7
    Smith NJ, Sak SC, Baldo O, Eardley I. The prevalence of newly diagnosed hyperlipidaemia in men with erectile dysfunction. BJU Int 2007; 100: 35761.
  • 8
    Azadzoi KM, Goldstein I. Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model. J Urol 1992; 147: 167581.
  • 9
    Kim JH, Klyachkin ML, Svendsen E, Davies MG, Hagen PO, Carson CC 3rd. Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. J Urol 1994; 151: 198205.
  • 10
    Nehra A, Azadzoi KM, Moreland RB, Pabby A, Siroky MB, Krane RJ, et al. Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J Urol 1998; 159: 222936.
  • 11
    Ryu JK, Shin HY, Song SU, Oh SM, Piao S, Han JY, et al. Downregulation of angiogenic factors and their downstream target molecules affects the deterioration of erectile function in a rat model of hypercholesterolemia. Urology 2006; 67: 132934.
  • 12
    Xie D, Odronic SI, Wu F, Pippen AM, Donatucci CF, Annex BH. A mouse model of hypercholesterolemia induced erectile dysfunction. J Sex Med 2007; 4 (4 Pt 1): 898907.
  • 13
    Byrne RR, Henry GD, Rao DS, Huynh TT, Pippen AM, Annex BH, et al. Vascular endothelial growth factor restores corporal smooth muscle function in vitro. J Urol 2001; 165: 13105.
  • 14
    Henry GD, Byrne R, Hunyh TT, Abraham V, Annex BH, Hagen PO, et al. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study. Int J Impot Res 2000; 12; 3349.
  • 15
    Xie D, Pippen AM, Odronic SI, Annex BH, Donatucci CF. Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit. J Sex Med 2006; 3: 22332.
  • 16
    Meurice T, Bauters C, Vallet B, Corseaux D, Van Belle E, Hamon M, et al. bFGF restores endothelium-dependent responses of hypercholesterolemic rabbit thoracic aorta. Am J Physiol 1997; 272: H6137.
  • 17
    Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr Opin Cardiol 2007; 22: 45863.
  • 18
    Kendirci M, Teloken PE, Champion HC, Hellstrom WJ, Bivalacqua TJ. Gene therapy for erectile dysfunction: fact or fiction? Eur Urol 2006; 50: 120822.
  • 19
    Huynh TT, Davies MG, Annex BH, Hagen PO. Tissue factor in the pathobiology of vein grafts. In: Vascular Surgery: Proceedings of the Third Congress of the Asian Vascular Society. WangZG, editor. International Academic Publishers. 1998; 3858.
  • 20
    Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99: 172632.
  • 21
    Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 175763.
  • 22
    Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. J Biol Chem 1998; 273: 3033643.
  • 23
    Kwak HJ, Lee SJ, Lee YH, Ryu CH, Koh KN, Choi HY, et al. Angiopoietin-1 inhibits irradiation and mannitol-induced apoptosis in endothelial cells. Circulation 2000; 101: 231724.
  • 24
    Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 35971.
  • 25
    Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, De Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 1997; 94: 71927.
  • 26
    De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med 2002; 12: 2416.
  • 27
    Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 782235.
  • 28
    Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169: 68191.
  • 29
    Xie D, Kontos CD, Donatucci CF, Annex BH. Cholesterol feeding reduces vascular endothelial growth factor signaling in rabbit corporal tissues. J Sex Med 2005; 2: 63440.
  • 30
    Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32: 11520.
  • 31
    Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993; 259: 191821.
  • 32
    Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64: 8418.
  • 33
    Morisada T, Kubota Y, Urano T, Suda T, Oike Y. Angiopoietins and angiopoietin-like proteins in angiogenesis. Endothelium 2006; 13: 719.
  • 34
    Burchardt T, Burchardt M, Chen MW, Buttyan R, De La Taille A, Shabsigh A, et al. Expression of VEGF splice variants 144/145 and 205/206 in adult male tissues. IUBMB Life 1999; 48: 4058.
  • 35
    Burchardt T, Burchardt M, Chen MW, Buttyan R, De La Taille A, Shabsigh A, et al. Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans. Biol Reprod 1999; 60: 398404.
  • 36
    Te AE, Santarosa RP, Koo HP, Buttyan R, Greene LA, Kaplan SA, et al. Neurotrophic factors in the rat penis. J Urol 1994; 152: 216772.
  • 37
    Haraguchi R, Suzuki K, Murakami R, Sakai M, Kamikawa M, Kengaku M, et al. Molecular analysis of external genitalia formation: the role of fibroblast growth factor (Fgf) genes during genital tubercle formation. Development 2000; 127: 24719.
  • 38
    Ogino Y, Suzuki K, Haraguchi R, Satoh Y, Dolle P, Yamada G. External genitalia formation: role of fibroblast growth factor, retinoic acid signaling, and distal urethral epithelium. Ann N Y Acad Sci 2001; 948: 1331.
  • 39
    Satoh Y, Haraguchi R, Wright TJ, Mansour SL, Partanen J, Hajihosseini MK, et al. Regulation of external genitalia development by concerted actions of FGF ligands and FGF receptors. Anat Embryol (Berl) 2004; 208: 47986.
  • 40
    Musicki B, Palese MA, Crone JK, Burnett AL. Phosphorylated endothelial nitric oxide synthase mediates vascular endothelial growth factor-induced penile erection. Biol Reprod 2004; 70: 2829.
  • 41
    Azadzoi KM. Vasculogenic erectile dysfunction: beyond the haemodynamic changes. BJU Int 2006; 97: 116.
  • 42
    Wang T, Soker S, Atala A, Siroky MB, Azadzoi KM. Alterations in angiogenic growth factors and neuronal nitric oxide synthase expression in chronic cavernosal ischemia. Int J Impot Res 2004; 16: 40311.
  • 43
    Xie D, Thompson MA, Pippen AM, Waters RE, Donatucci CF, Annex BH. Decreases in corporal vascular endothelial growth factor expression precede vasoreactivity changes in cholesterol fed rabbits. J Urol 2005; 173: 141822.
  • 44
    Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res 2007; 101: 94856.
  • 45
    Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191236.
  • 46
    Burnett AL, Calvin DC, Silver RI, Peppas DS, Docimo SG. Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol 1997; 158: 758.
  • 47
    Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005; 106: 23366.
  • 48
    Lin CS, Lue TF. Growth factor therapy and neuronal nitric oxide synthase. Int J Impot Res 2004; 16 (Suppl 1): S389.
  • 49
    Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 2004; 16 (Suppl 1): S159.
  • 50
    Burchardt M, Burchardt T, Anastasiadis AG, Buttyan R, De La Taille A, Shabsigh A, et al. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. Urology 2005; 66: 66570.
  • 51
    Peters KG. Vascular endothelial growth factor and the angiopoietins-working together to build a better blood vessel. Circ Res 1998; 83: 3423.
  • 52
    Ryu JK, Cho CH, Shin HY, Song SU, Oh SM, Lee M, et al. Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther 2006; 13: 70515.
  • 53
    Inoue Y, King TE, Barker E, Danilof E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 2002; 166: 76573.
  • 54
    Mulhall JP, Thom J, Lubrano T, Shankey TV. Basic fibroblast growth factor expression in Peyronie's disease. J Urol 2001; 165: 41923.
  • 55
    Cooper LT Jr, Hiatt WR, Creager MA, Regensteiner JG, Casscells W, Isner JM, et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 2001; 6: 2359.
  • 56
    Dai Q, Silverstein AD, Davies MG, Hagen PO, Donatucci CF, Annex BH. Systemic basic fibroblast growth factor induces favorable histological changes in the corpus cavernosum of hyper-cholesterolemic rabbits. J Urol 2003; 170 (2 Pt 1): 6648.
  • 57
    Kontos CD, Annex BH. Engineered transcription factors for therapeutic angiogenesis. Curr Opin Mol Ther 2007; 9: 14552.